Loading
A phase 2/3 trial testing LNS8801 in melanoma, now recruiting.
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma is a phase 2/3 interventional study registered as NCT06624644, led by Linnaeus Therapeutics, and recruiting on the registry. Official title: A Multicenter, Open-Label, Randomised, Controlled Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Treatment-Refractory, Unresectable Melanoma. Planned enrolment is 135 participants (estimated). The study started in 2025-08-06 and primary completion is expected in 2029-02. No results have been posted on ClinicalTrials.gov.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma.